A group of Merck scientists were awarded The Pharmaceutical Research and Manufacturers of America (PhRMA) Research and Hope Award for Biopharmaceutical Industry Research in Alzheimer's Disease. PhRMA represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to helping patients live longer, healthier and more productive lives. Fulfilling this mission often requires years of dedication.
The road to successful drug development is fraught with dead ends. In fact, out of every 5,000-10,000 compounds examined as potential treatments, only one will ever be approved by the Food and Drug Administration for patient use – in a process that could take as many as 15 years.
“Too often, the hard work and unwavering commitment by individuals who dedicate their lives to improving patient care go unrecognized. The Research and Hope Award honors those who rightly deserve credit for all of the sacrifices they have made to advance research and patient care in the fight against Alzheimer’s disease,” said PhRMA President and CEO John J. Castellani. “Despite the tremendous hurdles, the recipients of the Award have shown us that progress is not only possible, it is happening every day. Their achievements give hope to all of us, especially to patients and their families.”
The Merck team recognized for outstanding research in the search for a cure or treatment for Alzheimer’s disease included: Mark Forman, M.D., Ph.D., director, Clinical Research; Matthew Kennedy, Ph.D., associate director, Neuroscience; Eric Parker, Ph.D., senior director and Neuroscience site lead; Andrew Stamford, Ph.D., director, Discovery Chemistry; and Julie Stone, Ph.D., senior scientific director.
Merck understands that advancing medical knowledge about the course of Alzheimer's disease is important. This disease affects approximately 18 million people worldwide, and the number is expected to nearly double by 2025 to 34 million.Learn more